GB2461962B - Slow release NMDA receptor antagonist for otic disorders - Google Patents

Slow release NMDA receptor antagonist for otic disorders

Info

Publication number
GB2461962B
GB2461962B GB0907070A GB0907070A GB2461962B GB 2461962 B GB2461962 B GB 2461962B GB 0907070 A GB0907070 A GB 0907070A GB 0907070 A GB0907070 A GB 0907070A GB 2461962 B GB2461962 B GB 2461962B
Authority
GB
United Kingdom
Prior art keywords
receptor antagonist
slow release
nmda receptor
otic disorders
otic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0907070A
Other versions
GB2461962A (en
GB0907070D0 (en
Inventor
Jay Lichter
Andrew M Trammel
Fabrice Piu
Qiang Ye
Benedikt Vollrath
Sergio G Duryn
Luis A Dellamary
Carl Lebel
Michael Christopher Scaife
Jeffrey P Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Otonomy Inc
Original Assignee
University of California
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Otonomy Inc filed Critical University of California
Publication of GB0907070D0 publication Critical patent/GB0907070D0/en
Priority to PCT/US2009/048954 priority Critical patent/WO2010011466A2/en
Priority to US12/494,156 priority patent/US20090325938A1/en
Priority to US12/504,553 priority patent/US8496957B2/en
Priority to PCT/US2009/051078 priority patent/WO2010062413A1/en
Priority to EP09835529.0A priority patent/EP2299976A4/en
Priority to PCT/US2009/067552 priority patent/WO2010074992A2/en
Priority to JP2011542272A priority patent/JP6013736B2/en
Priority to CA2732686A priority patent/CA2732686C/en
Priority to AU2009330458A priority patent/AU2009330458B2/en
Priority to CN2009801305625A priority patent/CN102112111A/en
Priority to CN201610730867.1A priority patent/CN106344495A/en
Publication of GB2461962A publication Critical patent/GB2461962A/en
Priority to US12/767,461 priority patent/US8575122B2/en
Application granted granted Critical
Publication of GB2461962B publication Critical patent/GB2461962B/en
Priority to US13/425,217 priority patent/US8852626B2/en
Priority to US13/928,157 priority patent/US9066855B2/en
Priority to JP2015095099A priority patent/JP6207093B2/en
Priority to US14/713,944 priority patent/US9808460B2/en
Priority to US14/795,825 priority patent/US20150313839A1/en
Priority to US15/091,148 priority patent/US20170000728A1/en
Priority to JP2017087624A priority patent/JP2017160232A/en
Priority to JP2018083451A priority patent/JP2018138585A/en
Priority to US16/447,776 priority patent/US10918594B2/en
Priority to US17/146,909 priority patent/US20210220263A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0907070A 2008-06-27 2009-04-24 Slow release NMDA receptor antagonist for otic disorders Expired - Fee Related GB2461962B (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
PCT/US2009/048954 WO2010011466A2 (en) 2008-06-27 2009-06-26 Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US12/494,156 US20090325938A1 (en) 2008-06-27 2009-06-29 Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US12/504,553 US8496957B2 (en) 2008-07-21 2009-07-16 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
PCT/US2009/051078 WO2010062413A1 (en) 2008-07-21 2009-07-17 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
JP2011542272A JP6013736B2 (en) 2008-12-22 2009-12-10 Controlled release of an ear sensory cell modulator composition for the treatment of otic disorders and methods thereof
PCT/US2009/067552 WO2010074992A2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP09835529.0A EP2299976A4 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2732686A CA2732686C (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
AU2009330458A AU2009330458B2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN2009801305625A CN102112111A (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN201610730867.1A CN106344495A (en) 2008-12-22 2009-12-10 Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US12/767,461 US8575122B2 (en) 2008-07-21 2010-04-26 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US13/425,217 US8852626B2 (en) 2008-06-27 2012-03-20 Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US13/928,157 US9066855B2 (en) 2008-07-21 2013-06-26 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
JP2015095099A JP6207093B2 (en) 2008-12-22 2015-05-07 Controlled release of an ear sensory cell modulator composition for the treatment of otic disorders and methods thereof
US14/713,944 US9808460B2 (en) 2008-07-21 2015-05-15 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US14/795,825 US20150313839A1 (en) 2008-07-21 2015-07-09 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US15/091,148 US20170000728A1 (en) 2008-06-27 2016-04-05 Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders
JP2017087624A JP2017160232A (en) 2008-12-22 2017-04-26 Controlled release of auris sensory cell modulator compositions for treatment of otic disorders and methods therefor
JP2018083451A JP2018138585A (en) 2008-12-22 2018-04-24 Controlled release of auris sensory cell modulator compositions for the treatment of otic disorders and methods therefor
US16/447,776 US10918594B2 (en) 2008-06-27 2019-06-20 Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US17/146,909 US20210220263A1 (en) 2008-06-27 2021-01-12 Controlled-release cns modulating compositions and methods for the treatment of otic disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8383008P 2008-07-25 2008-07-25
US8609408P 2008-08-04 2008-08-04
US16023309P 2009-03-13 2009-03-13
US16481209P 2009-03-30 2009-03-30

Publications (3)

Publication Number Publication Date
GB0907070D0 GB0907070D0 (en) 2009-06-03
GB2461962A GB2461962A (en) 2010-01-27
GB2461962B true GB2461962B (en) 2011-02-16

Family

ID=40774914

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0907070A Expired - Fee Related GB2461962B (en) 2008-06-27 2009-04-24 Slow release NMDA receptor antagonist for otic disorders

Country Status (1)

Country Link
GB (1) GB2461962B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
WO2007038949A1 (en) * 2005-09-28 2007-04-12 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
CN101134780A (en) * 2007-07-09 2008-03-05 南京医科大学 Polypeptide analogue for blocking NR2B signal path and preparation method and medical usage thereof
WO2009120566A1 (en) * 2008-03-24 2009-10-01 Bausch & Lomb Incorporated Improved topical ophthalmic compositions
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
GB2459910A (en) * 2008-04-21 2009-11-11 Otonomy Inc Sustained release corticosteroid compositions for treatment of otic disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
WO2007038949A1 (en) * 2005-09-28 2007-04-12 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders
WO2007119098A2 (en) * 2005-09-28 2007-10-25 Auris Medical Ag Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
CN101134780A (en) * 2007-07-09 2008-03-05 南京医科大学 Polypeptide analogue for blocking NR2B signal path and preparation method and medical usage thereof
WO2009120566A1 (en) * 2008-03-24 2009-10-01 Bausch & Lomb Incorporated Improved topical ophthalmic compositions
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
GB2459910A (en) * 2008-04-21 2009-11-11 Otonomy Inc Sustained release corticosteroid compositions for treatment of otic disorders

Also Published As

Publication number Publication date
GB2461962A (en) 2010-01-27
GB0907070D0 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
IL208919A0 (en) Gpr119 receptor agonists
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
HK1144821A1 (en) Glucocorticoid receptor agonists
EP2151236A4 (en) G-protein-conjugated receptor agonist
HK1143136A1 (en) Pyridone gpr119 g protein-coupled receptor agonists
IL212550A0 (en) Apj receptor compounds
ZA201006587B (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
IL212545A0 (en) Toll-like receptor 3 antagonists
HK1136302A1 (en) Progesterone receptor antagonists
EP2184278A4 (en) P2x4 receptor antagonist
EP2427430A4 (en) 5-oxo-ete receptor antagonist compounds
EP2191830A4 (en) Solid preparation comprising npyy5 receptor antagonist
ZA201108724B (en) Toll-like receptor 3 antagonists
EP2153736A4 (en) Novel leukotriene receptor antagonist
ZA201003724B (en) Methods of identifying safe nmda receptor antagonists
EP2163557A4 (en) Function-selective vitamin d receptor agonist
EP2294082A4 (en) Compositions and methods for modulating nicotinic/nmda receptor function
GB2461962B (en) Slow release NMDA receptor antagonist for otic disorders
ZA201103984B (en) Toll-like receptor 3 antagonists

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20200424